These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 30623759)
1. [Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype]. Bertolotto C; Ohanna M; Ballotti R Med Sci (Paris); 2018 Dec; 34(12):1025-1028. PubMed ID: 30623759 [No Abstract] [Full Text] [Related]
3. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225 [TBL] [Abstract][Full Text] [Related]
5. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells. Ogino Y; Sato A; Uchiumi F; Tanuma SI Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964 [TBL] [Abstract][Full Text] [Related]
6. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Chen H; Wang S; Zhang H; Nice EC; Huang C Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719 [TBL] [Abstract][Full Text] [Related]
7. Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. Cea M; Soncini D; Gobbi M; Lemoli RM; Cagnetta A Expert Rev Anticancer Ther; 2016 Sep; 16(9):897-8. PubMed ID: 27433930 [No Abstract] [Full Text] [Related]
8. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612 [TBL] [Abstract][Full Text] [Related]
9. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Garten A; Schuster S; Penke M; Gorski T; de Giorgis T; Kiess W Nat Rev Endocrinol; 2015 Sep; 11(9):535-46. PubMed ID: 26215259 [TBL] [Abstract][Full Text] [Related]
10. NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. Indini A; Fiorilla I; Ponzone L; Calautti E; Audrito V Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077374 [TBL] [Abstract][Full Text] [Related]
11. Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). Audrito V; Managò A; Gaudino F; Deaglio S Semin Cell Dev Biol; 2020 Feb; 98():192-201. PubMed ID: 31059816 [TBL] [Abstract][Full Text] [Related]
12. A new standard of care for metastatic melanoma? Sharma SP Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559 [No Abstract] [Full Text] [Related]
13. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945 [TBL] [Abstract][Full Text] [Related]
14. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463 [TBL] [Abstract][Full Text] [Related]
15. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model. Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965 [TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders. Montecucco F; Cea M; Cagnetta A; Damonte P; Nahimana A; Ballestrero A; Del Rio A; Bruzzone S; Nencioni A Curr Top Med Chem; 2013; 13(23):2930-8. PubMed ID: 24171767 [TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104 [TBL] [Abstract][Full Text] [Related]
18. Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites. Buonvicino D; Mazzola F; Zamporlini F; Resta F; Ranieri G; Camaioni E; Muzzi M; Zecchi R; Pieraccini G; Dölle C; Calamante M; Bartolucci G; Ziegler M; Stecca B; Raffaelli N; Chiarugi A Cell Chem Biol; 2018 Apr; 25(4):471-482.e7. PubMed ID: 29478906 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099 [TBL] [Abstract][Full Text] [Related]
20. The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia. Chen X; Zhao S; Song Y; Shi Y; Leak RK; Cao G Curr Top Med Chem; 2015; 15(21):2211-21. PubMed ID: 26059356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]